News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
September 18, 2020
COMPASS Pathways announces pricing of upsized initial public offering
An announcement on the pricing of COMPASS Pathways' upsized initial public offering in the United States.
July 01, 2020
COMPASS Pathways News | July 2020 Issue
Here are highlights of our activities in the first half of 2020 as we work towards building a world of mental wellbeing for everyone.
June 23, 2020
COMPASS Pathways strengthens leadership team with appointment of Trevor Mill as Chief Development Officer
Announcement of our new appointments to our leadership team.
April 27, 2020
COMPASS Pathways concludes successful Series B investment round
Announcement of our successful $80m Series B investment round completion.
March 25, 2020
Protecting our communities and our teams during the COVID-19 pandemic
Letter from our co-founders explaining how we have changed our work to keep people safe during this pandemic.
January 15, 2020
COMPASS Pathways granted patent covering use of its psilocybin formulation in addressing treatment-resistant depression
Article discussing the granted psilocybin patent. Featuring a comment from co-founder George Goldsmith on what this means for COMPASS Pathways.
January 03, 2020
COMPASS Pathways News | December 2019 Issue
Here are highlights of our activities in the second half of 2019 that we hope will move us closer to our goal of improving mental health care for as many as possible.
December 12, 2019
COMPASS Pathways and King’s College London announce results from psilocybin study in healthy volunteers
An overview of the healthy volunteer study at Kings College London, where COMPASS Pathways COMP360 (psilocybin) was found to be well tolerated.